The prevention of recurrence after colorectal adenoma resection remains an urgent medical issue to be addressed. Previous studies have mainly focused on nonsteroidal anti-inflammatory drugs, calcium supplements, and vitamins. The gut microbiota and its metabolic products are believed to play a potential role in the development and progression of colorectal adenomas. Clostridium butyricum, a butyrate-producing probiotic, has not yet been studied for its potential in preventing the recurrence of colorectal adenomas following resection. Therefore, this study, designed as a multicenter, double-blind, placebo-controlled randomized controlled trial, aims to explore evidence-based data on the role of Clostridium butyricum in preventing colorectal adenoma recurrence.
Statistical Analysis Plan the intention-to-treat (ITT) population (all randomized participants analyzed according to the randomized assignment)-the primary analysis set; the per-protocol (PP) population (participants with ≥80% treatment compliance and no major protocol violations)-used for confirmatory efficacy consistency testing; and the safety analysis (SA) population (all randomized participants exposed to the investigational product or placebo with post-intervention safety data)-used for all safety evaluations. Primary Outcome Analysis Due to the asymptomatic nature of colorectal adenoma recurrence, which can only be detected at scheduled annual colonoscopic examinations, the time to recurrence is considered interval-censored data (i.e., the exact recurrence time is unknown, only that it occurred within a 12-month window between two consecutive colonoscopies). Given this data characteristic, the 3-year cumulative CRA recurrence rate will be estimated using the life table method, which divides follow-up time into 12-month intervals (0-12, 12-24, 24-36 months). Between-group comparisons of recurrence-free survival will be performed using the stratified log-rank test (stratified by participating center). Hazard ratios (HR) and corresponding 95% confidence intervals (CIs) will be estimated using a stratified Cox proportional hazards model. To ensure the robustness of the findings, sensitivity analyses using the Turnbull algorithm (an extension of the Kaplan-Meier method for interval-censored data) will also be conducted.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Enrollment
294
Oral Clostridium butyricum capsules, Live: take 3 capsules twice daily (bid) for the first 3 months after adenoma resection, then continue with 3 capsules once daily (qd) until 3 years post-resection (each capsule contains ≥6.3 × 10⁶ CFU of Clostridium butyricum).
Placebo capsules containing corn starch, with identical appearance, weight, and administration method as the treatment group.
the Affiliated Hospital of QIngdao University
Qingdao, Shandong, China
RECRUITINGWeifang People's Hospital
Weifang, Shandong, China
RECRUITINGThe 3-year cumulative recurrence rate of CRA
The 3-year cumulative recurrence rate of CRA following colonoscopic resection. Recurrence is defined as the identification of new or residual adenomatous polyps in the colorectum on colonoscopy during the follow-up period, confirmed pathologically.
Time frame: 3 years
1-year and 2 year adenoma recurrence rate
Each subject will undergo a colonoscopy once per year after enrollment to monitor for adenoma recurrence.
Time frame: 1-year and 2-year after enrollment
incidence of colorectal cancer
Each subject will undergo a colonoscopy once per year after enrollment to monitor for the development of colorectal cancer. The incidence of colorectal cancer is calculated as: Incidence (%) = (Number of subjects diagnosed with colorectal cancer / Total number of subjects) × 100%
Time frame: 3 years after enrollment
Incidence of advanced colorectal adenomas
Each subject will undergo a colonoscopy once per year after enrollment to monitor for the presence of advanced adenomas. The incidence of advanced adenomas is calculated as: Incidence (%) = (Number of subjects with advanced adenomas / Total number of subjects) × 100% Advanced colorectal adenoma is diagnosed when any of the following criteria are met: Adenoma diameter ≥ 10 mm,Villous component ≥ 25%,Presence of high-grade intraepithelial neoplasia.
Time frame: 3 years after enrollment
Location of adenoma recurrence
Classify the locations according to ascending colon, transverse colon, descending colon, sigmoid colon, and rectum.
Time frame: 3 years
Number of recurrent adenomas
Time frame: 3 years
Histological classification of recurrent adenomas
Classify the locations according to Tubular adenoma, Villous adenoma, Tubulovillous adenoma, Serrated adenoma
Time frame: 3 years
Size of recurrent adenomas
Measure the maximum diameter of the adenoma in millimeters
Time frame: 3 years
adenoma burden
Adenoma burden: the sum of the maximum diameters of all recurrent adenomas detected during follow-up.
Time frame: Assessed at 12, 24, and 36 months post-enrollment
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.